Therapy News and Research

RSS

Highlight Therapeutics presents positive Phase 2b topline results of intralesional BO‑112 in localized basal cell carcinoma as a late-breaker at EADV

Highlight Therapeutics, a clinical‑stage biotechnology company developing immune activators to transform the treatment of skin tumors, today announced positive results from the multicenter, single-arm Phase 2b SPOTLIGHT‑204 clinical trial evaluating BO‑112, a novel dsRNA-based intralesional treatment for patients with resectable primary low‑ and high‑risk basal cell carcinoma (BCC).

1 Oct 2026

GLP-1 receptor agonist exposure shows no link to major adverse pregnancy outcomes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health shows that, following a review and meta-analysis of available studies, use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) drugs for diabetes and weight management in women living with diabetes is not associated with adverse pregnancy outcomes in most cases.

1 Oct 2026

Early-onset type 2 diabetes trial demonstrates significant 24-week fat loss

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Regional Health Americas journal shows that in people who have developed early onset type 2 diabetes (EOT2D) (aged under 45 years), around half these T2D cases can be reversed with a low-energy diet combined with a structured exercise program.

1 Oct 2026

New antibiotic combinations aim to prevent recurrent bacterial vaginosis

Researchers and clinicians from Monash University and Bayside Health's Melbourne Sexual Health Centre are trialing new combinations of antibiotics to treat persistent bacterial vaginosis (BV), following their landmark discovery that the condition is sexually transmissible.

30 Sep 2026

Study examines the real-world use of GLP-1 RA drugs in children and young people

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has examined the real-world use of GLP-1 receptor agonist (GLP-1 RA) drugs in children and young people in Germany, Austria and Luxembourg.

30 Sep 2026

Insurance hurdles and costs hinder access to blood cancer drugs

Patients with blood cancers often face major insurance hurdles and significant out-of-pocket costs when trying to access specialty oral anticancer medications, according to a new nationwide study led by researchers at the Perelman School of Medicine at the University of Pennsylvania.

30 Sep 2026

Wearable device can track changes in stroke-related arm movement impairment

A team led by University of Massachusetts Amherst researchers has developed a wearable wrist device powered by a machine-learning algorithm that can continually track changes in arm movement impairment caused by strokes.

30 Sep 2026

Nuclear enzyme discovery unlocks new paths to combat breast cancer

One of the major challenges in the treatment of the most common subtype of breast cancer (hormone receptor positive, HR+) is the emergence of resistance.

30 Sep 2026

Scientists discover molecular pathway that controls cellular waste recycling

For years, TFEB has been regarded as one of the most promising therapeutic targets for restoring the cell's ability to clear and recycle waste.

30 Sep 2026

New mathematical model tracks how tumor environment impacts cancer therapies

Researchers from Mass General Brigham and the University of Cyprus have developed a sophisticated mathematical model to better understand how the tumor microenvironment affects the delivery and effectiveness of a new type of cancer therapy called an immunomodulatory antibody-drug conjugate (IM-ADC).

30 Sep 2026

Fractionated radiation reduces brain cancer recurrence and boosts survival

Mayo Clinic researchers led a multicenter study that found dividing radiation into several treatments, known as fractionated stereotactic radiosurgery, reduced the risk of cancer returning after surgery for brain metastases and was associated with improved survival compared with delivering radiation in a single treatment.

30 Sep 2026

Laverock Therapeutics announces in vivo programs in oncology and genetic medicine

Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announces its in vivo programs spanning CAR-T and genetic medicine

From Laverock Therapeutics 30 Sep 2026

Weekly cisplatin fails to reduce acute toxicity in advanced head and neck cancer

Physicians typically use either a higher dose of cisplatin given every three weeks or a lower dose given weekly in combination with radiation to treat locally advanced head and neck cancer.

29 Sep 2026

Petrelintide produces double-digit weight loss with fewer side effects

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Diabetes & Endocrinology shows that weekly injections with the new amylin-based obesity drug petrelintide can enable those treated to lose more than 10% of their body weight – generally lower than existing incretin-based (GLP-1 RA) drugs, but also with far fewer side effects.

29 Sep 2026

Study identifies three cell clusters driving pancreatic cancer-induced cachexia

Research published today in Cell identifies three small subclusters of cells driving pancreatic cancer-induced cachexia, a muscle-wasting and fat-loss condition that makes patients less tolerant of cancer treatment.

29 Sep 2026

Radioactive collagen tiles double survival for brain metastasis patients

A multicenter clinical trial led by researchers at The University of Texas MD Anderson Cancer Center has found that implanting collagen tiles during brain surgery to deliver targeted radiation therapy dramatically improved tumor control, lowered the risk of recurrence and improved overall survival compared to current standard of care for patients with newly diagnosed brain metastases in need of surgical resection.

29 Sep 2026

Tailored ACT+ may address psychological and supportive-care for cancer survivors

Advances in early diagnosis and cancer treatment mean that growing numbers of people are surviving cancer, with approximately 3.5 million people now living with and beyond the disease in the United Kingdom.

29 Sep 2026

Exercise therapy reduces knee osteoarthritis risk after ACL surgery

Exercise-based rehabilitation and education can reduce the chance of knee osteoarthritis following ACL reconstruction in people aged under 40, as well as improve pain and quality of life, a study by La Trobe University researchers has found.

29 Sep 2026

Experimental mRNA therapy protects the liver after acetaminophen overdose

When a patient arrives at the hospital with an acetaminophen overdose, it's often a race against the clock. The only FDA-approved antidote for overdose-related liver injury, N‑acetylcysteine, must be administered within hours to be effective.

28 Sep 2026

Five-session SBRT preserves quality of life before pancreatic cancer surgery

Patients preparing for pancreatic cancer surgery maintained better physical function and experienced less fatigue with five treatments of stereotactic body radiation therapy (SBRT) than with 28 treatments of conventional radiation therapy given with chemotherapy, according to a randomized phase 2 clinical trial.

28 Sep 2026